Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

807
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
807
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

5.6K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
5.6K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.4K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.4K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

14.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
14.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 study.

Haematologica·2026
Same author

Baseline platelet-to-lymphocyte ratio is associated with severe immune effector cell-associated toxicities in diffuse large B-cell lymphoma patients receiving anti-CD19 CAR T-cell therapy.

Frontiers in immunology·2026
Same author

Assessment tools for peripheral neuropathy in multiple myeloma.

The Korean journal of internal medicine·2026
Same author

Correction to "Highly Adaptive Kirigami-Metastructure Adhesive with Vertically Self-Aligning Octopus-like 3D Suction Cups for Efficient Wet Adhesion to Complexly Curved Surfaces".

ACS applied materials & interfaces·2026
Same author

Prognostic Factors for Relapse and the Role of Maintenance Therapy in Acute Promyelocytic Leukemia: A Real-World Multicenter Study in Korea.

Cancer research and treatment·2025
Same author

Leukemic Presentation of CD5-Positive Diffuse Large B-Cell Lymphoma: A Case Report and Literature Review.

Annals of clinical and laboratory science·2025

Related Experiment Video

Updated: Nov 7, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.1K

Immuno-oncology for B-cell lymphomas.

Yoon Seok Choi1

  • 1Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.

Blood Research
|May 3, 2021
PubMed
Summary

Cancer immunotherapy aims to enhance immune responses against tumors. For B-cell lymphomas, novel strategies targeting the tumor microenvironment are needed due to limitations of current active immunotherapies.

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Cancer immunotherapy seeks to re-establish anti-tumor immunity, progressing from antigen recognition to memory cell formation.
  • Active immunotherapies have shown promise in various cancers, but their efficacy in B-cell lymphomas is limited compared to passive immunotherapy, such as CAR T-cell therapy.

Purpose of the Study:

  • To review current understanding of the immune tumor microenvironment (TME) in B-cell non-Hodgkin lymphomas.
  • To discuss novel therapeutic strategies targeting the TME beyond immune checkpoint inhibition.

Main Methods:

  • Literature review of recent advancements in cancer immunotherapy and tumor microenvironment biology.
  • Analysis of therapeutic approaches for B-cell non-Hodgkin lymphomas.
Keywords:
ImmunotherapyLymphomaRegulatory T cellT cellVaccine

More Related Videos

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.9K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.5K

Related Experiment Videos

Last Updated: Nov 7, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.1K
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.9K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.5K

Main Results:

  • The TME plays a critical role in immune evasion within B-cell lymphomas.
  • Current active immunotherapies show limited clinical benefit in these malignancies.

Conclusions:

  • Understanding immune cell interactions within the TME is crucial for effective immunotherapy.
  • Novel TME-targeting therapies offer potential for improved treatment outcomes in B-cell lymphomas.